Predicting drug–drug interactions by graph convolutional network with multi-kernel

Author:

Wang Fei1,Lei Xiujuan2,Liao Bo3,Wu Fang-Xiang14

Affiliation:

1. Division of Biomedical Engineering, University of Saskatchewan, 57 Campus Drive, S7N 5A9, Saskatchewan, Canada

2. School of Computer Science, Shaanxi Normal University, 620 West Chang’an Avenue, 710119, Shaanxi, China

3. School of Mathematics and Statistics, Hainan Normal University, 99 Longkun South Road, 571158, Hainan, China

4. Department of Mechanical Engineering and Department of Computer Science, University of Saskatchewan, 57 Campus Drive, S7N 5A9, Saskatchewan, Canada

Abstract

Abstract Drug repositioning is proposed to find novel usages for existing drugs. Among many types of drug repositioning approaches, predicting drug–drug interactions (DDIs) helps explore the pharmacological functions of drugs and achieves potential drugs for novel treatments. A number of models have been applied to predict DDIs. The DDI network, which is constructed from the known DDIs, is a common part in many of the existing methods. However, the functions of DDIs are different, and thus integrating them in a single DDI graph may overlook some useful information. We propose a graph convolutional network with multi-kernel (GCNMK) to predict potential DDIs. GCNMK adopts two DDI graph kernels for the graph convolutional layers, namely, increased DDI graph consisting of ‘increase’-related DDIs and decreased DDI graph consisting of ‘decrease’-related DDIs. The learned drug features are fed into a block with three fully connected layers for the DDI prediction. We compare various types of drug features, whereas the target feature of drugs outperforms all other types of features and their concatenated features. In comparison with three different DDI prediction methods, our proposed GCNMK achieves the best performance in terms of area under receiver operating characteristic curve and area under precision-recall curve. In case studies, we identify the top 20 potential DDIs from all unknown DDIs, and the top 10 potential DDIs from the unknown DDIs among breast, colorectal and lung neoplasms-related drugs. Most of them have evidence to support the existence of their interactions. fangxiang.wu@usask.ca

Funder

Natural Science and Engineering Research Council of Canada

China Scholarship Council

National Natural Science Foundation of China

Publisher

Oxford University Press (OUP)

Subject

Molecular Biology,Information Systems

Reference32 articles.

1. Drug repurposing: progress, challenges and recommendations;Pushpakom;Nat Rev Drug Discov,2019

2. Drug repositioning based on comprehensive similarity measures and Bi-Random walk algorithm;Luo;Bioinformatics,2016

3. Computational drug repositioning with random walk on a heterogeneous network;Luo;IEEE/ACM Trans Comput Biol Bioinform,2018

4. Predicting drug-disease associations via using gaussian interaction profile and kernel-based autoencoder;Jiang;Biomed Res Int,2019

5. Identification of drug-disease associations using information of molecular structures and clinical symptoms via deep convolutional neural network;Li;Front Chem,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3